LifeSciences British Columbia is governed by a Board of Directors, whose members represent BC's biotechnology, medical devices, bioproducts & bioenergy, and life sciences industry. These elected directors provide guidance to LifeSciences British Columbia, set policy and ensure that the organization operates effectively in achieving its mandate, which is to facilitate a strong commercial economic development of the biotechnology and life sciences industry in BC.
As of our September 21, 2011 Annual General Meeting, the following people will comprise LifeSciences British Columbia's board of directors:
Doug Janzen - Cardiome Pharma Corp. - Chair
Simon Pimstone - Xenon Pharmaceuticals - Past Chair
Gordon McCauley - Allon Therapeutics - Vice Chair
John DeLucchi - PricewaterhouseCoopers - Treasurer
Joe Garcia - McCarthy Tétrault - Secretary
David Hall - Orange Advisory
Hector MacKay-Dunn, QC - Farris, Vaughan, Wills & Murphy LLP
Barry Allen - Urodynamix Technologies Ltd.
Paul Geyer - LightIntegra Technology
Ian Thomson - Canadian Bioenergy
Ali Tehrani - Zymeworks Inc.
Karimah Es Sabar - Centre for Drug Research & Development
Alan Winter - Genome British Columbia
Robin Ciceri - Research Universities' Council of British Columbia